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Abstract
Effective treatment of metastatic renal cell carcinoma (RCC) remains a major
medical concern, as these tumors are refractory to standard therapies and prognosis is poor. Although molecularly targeted therapies have shown some promise
in the treatment of this disease, advanced RCC tumors often develop resistance
to these drugs. Dissecting the molecular mechanisms underlying the progression
to advanced disease is necessary to design alternative and improved treatment
strategies. Tumor-associated macrophages (TAMs) found in aggressive RCC
tumors produce a variety of inflammatory cytokines, including interleukin-1b
(IL-1b). Moreover, the presence of TAMs and high serum levels of IL-1b in RCC
patients correlate with advanced disease. We hypothesized that IL-1b in the
tumor microenvironment promotes the development of aggressive RCC tumors
by directing affecting tumor epithelial cells. To address this, we investigated the
role of IL-1b in mediating RCC tumor cell invasion as a measure of tumor progression. We report that IL-1b induced tumor cell invasion of RCC cells through
a process that was dependent on the activity of matrix metalloproteinases
(MMPs) and was independent of migration rate. Specifically, IL-1b induced the
expression of MMP-1, MMP-3, MMP-10, and MT1-MMP in a mechanism
dependent on IL-1b activation of the transcription factor CCAAT enhancer binding protein b (CEBPb). Consistent with its role in MMP gene expression, CEBPb
knockdown significantly reduced invasion, but not migration, of RCC tumor
cells. These results identify the IL-1b /CEBPb/MMP pathway as a putative target
in the design of anti-metastatic therapies for the treatment of advanced RCC.

Introduction
For 2012, it is predicted that nearly 65,000 new cases of
cancer of the kidney and renal pelvis will be diagnosed,
and approximately 13,500 of those patients will die from
disease-specific causes [1]. Renal cell carcinoma (RCC) is
the most common urological cancer and represents the
seventh most common cancer in men and the ninth most
common cancer in women. When diagnosed and treated
early, localized RCC has an excellent prognosis, with 90%
of patients surviving beyond 5 years from diagnosis [2].
However, many RCC patients are asymptomatic, and the
malignancy may go undetected for some time. This delay
in diagnosis is reflected by the observation that approxi-

mately 30% of RCC patients present with metastatic
disease at the time of diagnosis [3]. Prognosis for patients
with metastatic disease is poor compared to patients with
localized cancer, with the 5-year survival rate dropping to
11% for metastatic patients [2]. In fact, the majority of
RCC patients with metastatic disease will not survive 6
months beyond diagnosis. Therefore, understanding
the molecular pathways involved in RCC metastasis will
identify novel targets for the treatment of this disease.
Clear cell RCC, the most common form of kidney cancer,
is genetically linked to the von Hippel Lindau (VHL) tumor
suppressor gene in familial and sporadic cases [4]. VHL
functions normally to destabilize hypoxia-inducible factor
alpha (HIF-a) protein, a key transcription factor that drives

ª 2012 The Authors. Published by Blackwell Publishing Ltd. This is an open access article under the terms of the Creative
Commons Attribution Non-Commercial License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited and is not used for commercial purposes.
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renal tumorigenesis. Dysregulated expression of HIF-a as a
direct consequence of VHL inactivation results in tumors
that display a hypoxic phenotype, even when the tumor
microenvironment is not in fact hypoxic. As a result, clear
cell RCC tumors overexpress proangiogenic factors, such as
vascular endothelial growth factor (VEGF), and are highly
vascularized [4]. It is well accepted that tumor angiogenesis
is directed, in part, by inflammatory mediators in the
microenvironment, such as those expressed by tumor-associated macrophages (TAMs) [5]. In particular, the proinflammatory cytokine, interleukin-1b (IL-1b), has been
shown to be important in promoting tumor angiogenesis.
Studies in mouse models have demonstrated that inhibition
of IL-1b signaling, although IL-1 receptor antagonists or
knockout of the IL-1b gene, reduced tumor blood vessel
formation [6]. TAMs isolated from RCC tumors express
high levels of inflammatory cytokines, including IL-1b,
tumor necrosis factor a (TNFa), and interleukin-6
(IL-6; [7]). The presence of TAMs and high serum levels of
these cytokines are poor prognostic factors in RCC patients,
indicating that an inflammatory microenvironment may
promote RCC tumor progression [8–10].
In addition to its role in angiogenesis, we hypothesized that
IL-1b contributes to the progression of RCC by directly
affecting tumor cell invasion. Our results show that IL-1b
potently induced the invasiveness of VHL null RCC cells, a
process that required the activity of the matrix metalloproteinase (MMP) family of endopeptidases. Collectively, the
MMPs degrade every component of the extracellular matrix
(ECM) as well as nonmatrix proteins, such as growth factors, adhesion molecules, and other MMPs. Overexpression
of MMPs is associated with the progression of many
human cancers [11]. We demonstrate that IL-1b induced
the expression of the secreted MMPs: MMP-1 (Collagenase-1), MMP-3 (Stromelysin-1), MMP-10 (Stromelysin2), and the transmembrane MMP, MT1-MMP (MMP-14),
in RCC cells. In addition, the mechanism of IL-1b-induced
MMP expression was mediated by CCAAT enhancer binding protein b (CEBPb). CEBPb is a basic leucine zipper
(bZIP) transcription factor shown to contribute to the
pathogenesis of breast cancer [12]. Consistent with this,
our data show that IL-1b-induced RCC tumor invasion
was dependent on CEBPb. We conclude from this study
that the IL-1b/CEBPb/MMP pathway is a major mediator
of RCC tumor invasion and should be considered in the
design of molecularly targeted therapeutics.

Material and Methods
Cell culture and treatments
The human 786-0 RCC cell line (American Type
Culture Collection, Manassas, VA) is null for VHL
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expression [13]. Cells were maintained in Dulbecco’s
Modified Eagle’s Medium (Mediatech, Inc., Herndon,
VA) supplemented with 10% fetal bovine serum (FBS;
Hyclone, Logan, UT), penicillin (100 U/mL) and streptomycin (100 g/mL), and cultured at 37°C, 5% CO2. For
serum-free conditions, culture medium without supplementation of FBS was used. Cells were washed three times
with Hank’s Balanced Salt Solution (HBSS; Mediatech,
Inc.) prior to treatment in serum-free conditions. IL-1b
(R&D Systems, Minneapolis, MN) was used at the indicated concentrations and times. GM6001 (Millipore, Inc.,
Bellerica, MA), was prepared in DMSO and used at
25 lM. An equal volume of DMSO was used as a vehicle
control.

Stable transfection
The 786-0 cells were transfected to stably express SA
Biosciences (Valencia, CA) SureSilencing CEBPb shRNA
(Cat no. KH00991N) or a control scrambled
shRNA using Lipofectamine 2000TM Transfection Reagent
(Invitrogen, Carlsbad, CA) following manufacturer’s
instructions. Cells were allowed to recover in fresh
DMEM + 10% FBS for 24 h before selection. Transfected
cells were diluted 1:1000 and selected with culturing
media containing 1 lg/mL G418 for approximately
2 weeks. Individual colonies were picked and expanded
for analysis and cultured under continuous selection.
CEBPb knockdown in the polyclonal population and in
the individual clones was assessed through Western blotting of whole cell extracts. Scrambled shRNA clones were
selected for further analysis if they expressed comparable
levels of CEBPb as the 786-0 parental cells. CEBPb
shRNA-expressing cells displaying >50% knockdown
compared to scrambled shRNA control cells were used in
experiments.

Immunoblotting
Whole cell lysates were harvested from confluent 6-well
with 29 sample buffer (Sigma Chemical, St. Louis,
MO). Secreted proteins were isolated from conditioned
media using trichloroacetic acid (TCA) precipitation.
Samples were resolved by SDS-PAGE as previously
described [14]. Blots were probed with antibodies to
total CEBPb (Santa Cruz Biotechnology, Santa Cruz,
CA), phospho-CEBPb (Thr235), and actin (Cell
Signaling Technology, Beverly, MA), MMP-1 (Millipore,
Inc.), MMP-3 (R&D Systems), MMP-10 (R&D
Systems), and MT1-MMP (Millipore, Inc.). Proteins
were visualized using the ThermoPierce Biotechnology
(Rockford, IL) Supersignal West Pico or Femto
detection kits.

© 2012 The Authors. Published by Blackwell Publishing Ltd.
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The 786-0 cells were seeded at a density of 2 9 104 cells/
well of an 8-well Lab-Tek Chambered #1.0 Borosilicate
Coverglass System (Thermo Fisher Scientific, Waltham,
MA). Cells were treated overnight in serum-free media in
the presence or absence of 1 ng/mL IL-1b. The following
day, cells were fixed with 4% paraformaldehyde at room
temperature for 15 min. Antigens were blocked at room
temperature for 30 min with a blocking buffer containing
19 PBS, 10% normal goat serum, 1% BSA, and 0.3%
Triton X-100. Cells were washed with 19 PBS + 1% BSA
between each step. The human EMT 3-color immunocytochemistry kit (R&D Systems) was used for analysis of
EMT markers, Vimentin, E-Cadherin and Snail, according
to the manufacturer’s instructions. For analysis of CEBPb
expression, blocked cells were incubated at room temperature for 2 h with anti-CEBPb antibody (sc-150, Santa
Cruz Biotechnology) diluted 1:100 in blocking buffer. No
primary antibody was added in control wells to account
for background fluorescence. Goat anti-rabbit Alexa 488
secondary antibody (Invitrogen) was added in blocking
buffer at (10 lg/mL) and incubated for an additional
hour at room temperature in the dark. Before viewing,
cells were thrice washed with 19 PBS + 1% BSA and
ProLong® Gold Antifade Reagent (Invitrogen) was added
as a DAPI nuclear counterstain. Immunofluorescence was
viewed using a Nikon 90i inverted phase contrast microscope using 209 and 409 objectives, as indicated,
and analyzed using NIS Elements Advanced Research
software.

previously described with a few modifications [18].
Briefly, collagen was prepared from purified bovine type I
collagen (Trevigen, Gaithersburg, MD) following manufacturer’s instructions. Collagen was neutralized with the
addition of 109 PBS and 7.5% sodium bicarbonate.
FluoroBlokTM membranes were coated with 100 lL per
cm2 growth area with collagen diluted to 1 mg/mL. The
collagen was allowed to gel on top of the transwell membranes at 37°C overnight. Cells for migration or invasion
assays were serum-starved overnight with or without
treatment, as indicated, before being harvested for assays.
The next day, cells were seeded on top of the collagen
layer (for invasion assays) or on top of the FluoroblokTM
membrane (for migration assays) at a density of 2 9 104
cells per insert in serum-free media containing 1 ng/mL
IL-1b or no treatment. DMEM + 10% FBS was added to
the lower chamber as a chemoattractant, and cells were
allowed to invade or migrate for 24 h. Invaded cells
were stained with Calcein AM (4 lM, Invitrogen) and
viewed using fluorescence microscopy using a Nikon
Eclipse TS100 inverted microscope equipped with Spot
digital software. Micrographs were taken using a 29
objective. Images were imported into Image J and
converted to a threshold image for analysis. Cell numbers
were derived from threshold counts of the outlines of
cells with a circularity of 0.00–1.00 and an area size
exclusion of <15 (pixel2). Each condition was run in
triplicate and repeated at least three times. Data are presented as average fold induction of untreated samples
derived from the average threshold count of triplicate
samples.

Real-time RT-PCR

FITC-collagen degradation assay

Purification of total cellular RNA, reverse transcription,
and real-time PCR reactions were all performed as
described previously [14]. Briefly, for each experiment,
triplicate samples were obtained, and the cDNA for each
was assayed in duplicate. A quantity of 50 ng of input
cDNA was used in each real-time PCR reaction, and
amplification was measured using the following parameters: 95°C 10 min, 40 cycles of 95°C 15 sec, 60°C
1 min, and a plate read. Primer sequences were as published previously [15, 16]. Data are presented as relative
expression as calculated using 2 DDC(T) method [17].

786-0 cells were treated overnight in serum-free media
alone or supplemented with 1 ng/mL IL-1b. The following day, cells were harvested by trypsinization, and
1 9 105 cells were resuspended in 1 mL serum-free
media in the presence or absence of IL-1b. An equal
volume of cells (250 lL) was added to an equal
volume (250 lL) of a collagen mixture and applied to a
24-well plate (n = 3) for a final collagen concentration of
1 mg/mL. The collagen was prepared as a 2 mg/mL mixture of purified bovine type I collagen (Trevigen) and a
bovine type I FITC-collagen conjugate (Sigma-Aldrich,
St. Louis, MO). Collagen was neutralized with the
addition of 109 PBS and 7.5% sodium bicarbonate. The
cell-embedded collagen was allowed to solidify overnight at 37°C before 500 lL of prewarmed serumfree media (±IL-1b @ 1 ng/mL) was added to the top of
the gel. The following day, 100 lL of media was transferred, and fluorescence of the media was measured at
490/520.

Immunofluorescence

Migration and collagen invasion assays
HTS FluoroBlokTM inserts (BD Falcon Labware, 6.5 mm,
Franklin Lakes, NJ) were used for both migration and
invasion assays. Migration assays were performed as
described below without the inclusion of a collagen
matrix. Invasion assays were essentially performed as

© 2012 The Authors. Published by Blackwell Publishing Ltd.
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Statistical analysis
Statistical significance was calculated using the student’s
t-test available at http://www.physics.csbsju.edu/stats/
t-test.html and is represented as ± standard deviation (SD)
of the mean. Significance was assigned to P-values <0.05.

Results
IL-1b induces RCC tumor cell invasion
To begin our investigation of whether the inflammatory
cytokine, IL-1b, promoted an invasive phenotype in RCC,
we first measured whether or not IL-1b treatment
induced collagen invasion of the human 786-0 VHL null
RCC cell line. The tumor stromal microenvironment is
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primarily comprised of type I collagen; therefore, tumor
cells must breach this matrix barrier to invade the surrounding tissue [19]. Furthermore, type I collagen is the
major protein constituent of bone. Procollagen type I
amino-terminal propeptide, a marker of type I collagen
metabolism, is significantly elevated in RCC patients with
bone metastases [20]. Thus, RCC degradation and invasion of type I collagen has important clinical implications.
The 786-0 cells were serum-starved overnight in the presence or absence of IL-1b before being seeded on top of
type I collagen-coated transwells in the presence or
absence of IL-1b stimulation. Treatment of the RCC cells
with IL-1b resulted in induction of tumor cell invasion
by 24 h (Fig. 1A).
Tumor cell invasion is a multi-step process beginning
with the ability of a cell to individually migrate and to

Figure 1. IL-1b induces collagen invasion and degradation. (A) 786-0 RCC cells were treated overnight in serum-free media either alone or
containing 1 ng/mL IL-1b. The next day, cells were harvested for an invasion assay as described in the Methods and were allowed to invade
overnight. Values are presented as average fold induction of untreated cells, error bars are standard deviation of the mean; P < 0.005. (B) 786-0
RCC cells were treated overnight in serum-free media alone or containing 1 ng/mL IL-1b. The next day, cells were harvested for a migration assay
as described in the Methods and were allowed to migrate overnight. Values are presented as average fold induction of untreated cells. (C) 786-0
RCC cells were seeded onto glass chamber slides and were untreated or treated with 1 ng/mL IL-1b in serum-free media overnight. Cells were
fixed in 4% paraformaldehyde and incubated with fluorochrome-conjugated antibodies against Vimentin (green), E-Cadherin (red), and Snail
(orange). Cells were counter-stained with ProLong® Gold Antifade Reagent (DAPI, blue). (D) 786-0 RCC cells were untreated or treated with
1 ng/mL IL-1b in serum-free media overnight. The next day, cells were harvested and subjected to the FITC collagen degradation assay as
described in the Methods. Values represent average relative fluorescence units of triplicate samples; P < 0.0001. (E) 786-0 RCC cells were treated
overnight in serum-free media either alone or containing 1 ng/mL IL-1b. The next day, cells were harvested for an invasion assay as described in
the Methods with the following treatments: (1) no treatment + DMSO, (2) no treatment + 25 lM GM6001, (3) 1 ng/mL IL-1b + DMSO or (4)
1 ng/mL IL-1b + 25 lM GM6001. Cells were allowed to invade for 24 h. Values are presented as average fold induction of untreated cells, error
bars are standard deviation of the mean; P < 0.005.
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modify the ECM [21]. We next tested whether or not
IL-1b stimulation affected tumor cell migration using a
transwell migration assay lacking a collagen matrix substrate. The 786-0 cells were serum-starved overnight in
the presence or absence of IL-1b before being harvested
for the migration assay. IL-1b had no effect on the migration of the 786-0 cells, which displayed high levels of
basal migration at 24 h (Fig. 1B). In agreement, IL-1b
treatment had no effect on the expression of classic epithelial–mesenchymal transition (EMT) markers, as this
cell line already displayed an EMT signature, determined
by the expression of vimentin and nuclear Snail and the
loss of expression of E-cadherin (Fig. 1C; [22]). These
results are consistent with a report that activation of the
VHL-HIF pathway results in loss of E-cadherin expression, suggesting that VHL null RCC cells undergo EMT
at an early stage in tumorigenesis [23].
Next, the ability of the RCC cells to modify a type I
collagen matrix in response to IL-1b treatment was
assessed. IL-1b stimulated 786-0 cells were embedded
within a semi-solid collagen matrix impregnated with a
FITC-collagen conjugate. After 24 h in the presence or
absence of IL-1b treatment, cleaved FITC-collagen
released into the overlying media was quantified. IL-1binduced type I collagen degradation (Fig. 1D) by the
RCC cells, suggesting that IL-1b-induced cell invasion is
mediated by cleavage of the collagen substrate. Because
type I collagen degradation requires the enzymatic activity

IL-1b Promotes RCC Tumor Invasion

of the MMPs [19], we tested whether or not IL-1binduced tumor invasion was MMP-dependent. Treatment
of the RCC cells with GM6001, a pan-MMP inhibitor,
blocked IL-1b-induced invasion (Fig. 1E), demonstrating
a role for MMPs in this process.

IL-1b potently induces MMP expression in
RCC cells
Since IL-1b promoted MMP-dependent type I collagen
invasion by RCC cells, we next measured the effect of
IL-1b on MMP gene and protein expression. Specifically,
we focused our analysis on MMPs with type I collagenase
activity. Overexpression of MMPs has been associated
with several steps in tumorigenesis, such as proliferation,
apoptosis, inflammatory response, and tumor invasion
and metastasis [11]. The 786-0 cells were treated overnight with 0.1–100 ng/mL IL-1b in serum-free media or
serum-free media alone, and total RNA and protein were
harvested for analyses. IL-1b potently induced the expression of MMP-1, MMP-3, and MMP-10 at both the
mRNA and protein levels in a dose-responsive manner
(Fig. 2A–D). MMP-1 collagenase is primarily responsible
for cleaving type I collagen found in the tumor stroma.
Both MMP-3 and MMP-10 activate MMP-1 and degrade
noncollagen ECM proteins [19]. Importantly, MMP-3
and MMP-10 are often coordinately regulated with
MMP-1.

Figure 2. IL-1b induces MMP expression in a
dose-responsive manner in RCC cells. 786-0
RCC cells were treated overnight in serum-free
media in the presence or absence of 0.1–
100 ng/mL IL-1b. The following day, total RNA
was harvested, and gene expression was
analyzed by real-time PCR for MMP-1 (A),
MMP-3 (B), MMP-10 (C), and MT1-MMP (D).
Data represent MMP gene expression
normalized to GAPDH and calculated as
average fold induction of untreated cultures;
P < 0.0001. (E) 786-0 RCC cells were treated
overnight in serum-free media in the presence
or absence of 0.1–10 ng/mL IL-1b. The
following day, total protein was harvested, and
media from the cultures were subjected to
TCA precipitation for protein analysis of the
secreted MMPs. Protein expression analyses of
MMP-1, -3, -10, MT1-MMP, and actin were
performed using Western blotting.

© 2012 The Authors. Published by Blackwell Publishing Ltd.
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MT1-MMP (MMP-14) is a transmembrane protein
important for pericellular proteolysis of type I collagen
[24]. We previously published that MT1-MMP is regulated by the VHL-HIF pathway and is constitutively
expressed in VHL null RCC cells [16], unlike the secreted
MMPs (MMP-1, MMP-3, MMP-10), which are not
basally expressed in these cells. Constitutive expression of
MT1-MMP was mildly induced by IL-1b treatment
(Fig. 2D and E). Another collagenase, MMP-13 (collagenase-2), was not expressed in these cells either basally or
in response to IL-1b treatment (data not shown). Interestingly, mRNA expression of all four MMPs was maximally induced with 1 ng/mL IL-1b, suggesting that the
IL-1b signaling pathway is saturated at this concentration.
Therefore, subsequent experiments were conducted using
1 ng/mL IL-1b.

B. L. Petrella & M. P. Vincenti

MMP-1, MMP-3, and MMP-10 mRNA expression was
induced as early as 2 h by IL-1b and maximally induced
by 24 h (Fig. 3A–C). Induced protein levels of MMP-1,
MMP-3, and MMP-10 were detected by 8 h and
maximum expression was reached by 24 h posttreatment
(Fig. 3E). In contrast, MT1-MMP mRNA was not
induced until 24 h of IL-1b treatment, and MT1-MMP
protein levels remained relatively constant throughout the
24-h timecourse (Fig. 3E).

IL-1b induces CEBPb expression in RCC cells
CEBPb is a bZIP transcription factor that responds to
inflammatory signals [25]. Importantly, CEBPb activation
has been correlated with increased invasiveness of RCC
tumors in patients, suggesting it plays a role in the pro-

Figure 3. IL-1b induces MMP expression in a time-dependent manner in RCC cells. 786-0 RCC cells were treated overnight in serum-free media
in the presence or absence of 1 ng/mL IL-1b. At 2, 4, 8, and 24 h posttreatment, total RNA was harvested, and gene expression was analyzed by
real-time PCR for MMP-1 (A), MMP-3 (B), MMP-10 (C), and MT1-MMP (D). Data represent MMP gene expression normalized to GAPDH and
calculated as average fold induction of untreated cultures; P < 0.0001. (E) 786-0 RCC cells were treated overnight in serum-free media in the
presence or absence of 1 ng/mL IL-1b. At 2, 4, 8, and 24 h posttreatment, total protein was harvested, and media from the cultures were
subjected to TCA precipitation for protein analysis of the secreted MMPs. Protein expression analyses of MMP-1, -3, -10, MT1-MMP, and actin
were performed using Western blotting.
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cess of tumor cell invasion [26]. Previously, we published
that IL-1b induces MMP gene expression in non-small
cell lung carcinoma and chondrosarcoma cells, and that
IL-1b induction of MMP gene expression in these cancer
lines is dependent on the transcriptional activity of the
CEBPb [14, 15]. Therefore, we next investigated whether
IL-1b induced the expression and/or activation of CEBPb.
786-0 cells were treated with 0.1–10 ng/mL IL-1b for
24 h, or at 1 ng/mL in a timecourse experiment (2–24 h),
and total protein was isolated for analyses. Similar to the
MMP response to IL-1b treatment, total CEBPb protein
was potently induced by IL-1b treatment at 1 ng/mL, and
was measurably induced by 2–4 h of IL-1b treatment
(Fig. 4A and B). Phosphorylation of CEBPb at threonine
235 mediates the transcriptional activity of this transcription factor [25]. IL-1b-induced phosphorylation at this
site was dose-responsive, and P-CEBPb was detectable
by 2 h posttreatment (Fig. 4A and B). Furthermore,
IL-1b-induced CEBPb was detected in the nuclei of
stimulated cells as measured by immunofluorescence
(Fig. 4C). Together, these data demonstrate that IL-1b
induces CEBPb expression and activation in RCC cells.

CEBPb regulates IL-1b-induced MMP
expression in RCC cells
Our data thus far suggest that IL-1b-induced collagen
invasion is mediated through the induction of MMP
expression and the subsequent collagenolytic events that
result from their activity. We next asked whether or not
IL-1b-induced MMP expression was dependent on IL-1bregulated CEBPb expression. To this end, we generated
stable cell lines that expressed either a scrambled shRNA
or an shRNA specifically targeting CEBPb. Stable expression of this shRNA significantly reduced basal and IL-1binduced CEBPb expression in the 786-0 cells (Fig. 5A).
Knockdown of CEBPb blocked IL-1b-induced MMP-1,
MMP-3, and MMP-10 expression at both the mRNA and
protein levels (Fig. 5B–D,F) with no effect on basal levels
(data not shown). Although the high constitutive expression of MT1-MMP mRNA and protein were modestly
induced by IL-1b compared to the other MMPs, this
induction was also dependent on CEBPb (Fig. 5E and F).
These data demonstrate that CEBPb is required for IL-1b
induction of MMP expression in RCC cells.

CEBPb mediates IL-1b-induced RCC tumor
cell invasion
Since we demonstrated that IL-1b-induced collagen invasion of RCC cells was dependent on MMP enzymatic
activity (Fig. 1E) and that IL-1b-induced MMP expression was dependent on CEBPb (Fig. 5), we next asked

© 2012 The Authors. Published by Blackwell Publishing Ltd.

Figure 4. IL-1b induces CEBPb expression and phosphorylation in
RCC cells. (A) 786-0 RCC cells were treated overnight in serum-free
media in the presence or absence of 0.1–100 ng/mL IL-1b. The
following day, total protein was harvested and immunoblotted for
phospho-CEBPb (Thr235), total CEBPb, and actin. (B) 786-0 RCC cells
were treated overnight in serum-free media in the presence or
absence of 1 ng/mL IL-1b. At 2, 4, 8 and 24 h posttreatment, total
protein was harvested and immunoblotted for phospho-CEBPb
(Thr235), total CEBPb, and actin. (C) 786-0 RCC cells were seeded
onto glass chamber slides for immunofluorescence analysis of CEBPb
as described in the Methods. The next day, cells were untreated or
treated with 1 ng/mL IL-1b in serum-free media overnight before
fixation. Immunofluorescent expression of CEBPb was visualized using
Alexa 488-conjugated secondary antibodies (CEBPb, green). Cells
incubated with no primary antibody were included as a negative
control for background fluorescence. Cells were counter-stained with
ProLong® Gold Antifade Reagent (DAPI, false-colored red).
Micrographs were taken using a 209 or 409 objective, as indicated.
Merged images of CEBPb expression and DAPI stain appear yellow.

whether or not CEBPb was required for IL-1b-mediated
RCC tumor cell invasion. The stable scrambled shRNA
and CEBPb shRNA-expressing cell lines were treated
overnight in serum-free media in the presence or absence
of 1 ng/mL IL-1b before being seeded on top of type I
collagen-coated transwells, as in Figure 1. CEBPb knockdown significantly decreased IL-1b-induced tumor cell
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Figure 5. IL-1b-induced MMP expression is
dependent on CEBPb. Stable lines of 786-0
cells expressing either a scrambled shRNA or a
CEBPb-targeting shRNA were generated.
Subconfluent cultures of individual clonal
stable lines were treated overnight in serumfree media in the presence or absence of 1 ng/
mL IL-1b. The following day, total RNA was
harvested, and gene expression was analyzed
by real-time PCR for MMP-1 (A), MMP-3 (B),
MMP-10 (C), and MT1-MMP (D). Samples
were performed in triplicate and experiments
repeated twice. Data represent MMP gene
expression normalized to GAPDH and
calculated as average fold induction of
untreated samples; P < 0.0001. (E) Stable
polyclonal lines were treated overnight in
serum-free media in the presence or absence
of 1 ng/mL IL-1b. The following day, total
protein was harvested, and media from the
cultures were subjected to TCA precipitation
for protein analysis of the secreted MMPs.
Protein expression analyses of total CEBPb,
MMP-1, -3, -10, MT1-MMP, and actin were
performed using Western blotting.

invasion (Fig. 6A). Importantly, CEBPb knockdown had
no effect on the migratory behavior of these cells at 24 h
(Fig. 6B), suggesting that the IL-1b/CEBPb/MMP axis
specifically enables the cells to modify the collagen barrier
present in the invasion assay. These studies demonstrate
an important role for CEBPb in mediating IL-1b-induced
RCC tumor cell invasion.

Discussion
Despite advances in our understanding of kidney tumor
biology, metastatic RCC remains difficult to treat.
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Contributing to the low survival rate of advanced RCC
patients is the fact that this cancer is refractory to chemotherapy and radiation. For years, the standard of care
was immunotherapy in the form of high doses of
interleukin-2 (IL-2) and/or interferon-a (INF-a). Unfortunately, patients suffered from acute toxicity, and the
complete response rate was low [27]. Recently, molecularly targeted therapies, such as VEGF signaling inhibitors
(sorafenib, sunitinib, bevacizumab) and mTOR inhibitors
(everolimus, temsirolimus) have become FDA-approved
as front-line therapy for RCC patients [28]. Although the
adverse effects of these treatments are, in general, better

© 2012 The Authors. Published by Blackwell Publishing Ltd.

B. L. Petrella & M. P. Vincenti

Figure 6. IL-1b-mediated collagen invasion of RCC cells is dependent
on CEBPb. Stable scrambled or CEBPb shRNA 786-0 cells were treated
overnight in serum-free media either alone or containing 1 ng/mL IL1b. The next day, cells were harvested for the invasion assay (A) or
migration assay (B) as described in the Methods and were allowed to
invade or migrate for 24 h. Values are presented as average fold
induction of untreated cells; P < 0.05.

tolerated compared to immunotherapy, tumors often
develop resistance to these drugs. Furthermore, while the
overall survival and progression-free survival rates of targeted therapies show improvement over cytokine therapy,
curative rates are not superior [28]. Therefore, identifying
new molecular targets in the biology of this cancer is
important for the continued development of effective,
well tolerated therapies.
In this report, we investigated the role of the inflammatory cytokine, IL-1b, in RCC tumor cell invasiveness as a
key characteristic of a tumor cell’s progression to metastatic disease. Our results indicate that IL-1b is sufficient
to induce tumor cell invasion of RCC cells (Fig. 1).
Moreover, IL-1b potently induced the expression of
MMP-1, MMP-3, and MMP-10 and mildly induced the
expression of MT1-MMP (Fig. 2). Of note, high levels of
MMP-10 correlate with advanced stages of RCC, and
MMP-10 is a poor prognostic factor for survival [29].
Expression of MMP-1, MMP-3, MMP-10 was coordi-
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nately upregulated by IL-1b, with mRNA expression
detected as early as 2 h posttreatment (Fig. 3). It is possible that these MMPs are upregulated in an early response
to IL-1b stimulation via direct interaction of CEBPb at
the promoters of these genes. In support of this hypothesis, we previously characterized a CEBPb binding site at
-2921 of the MMP-1 promoter and identified putative
CEBPb binding sites in the promoters of MMP-3 and
MMP-10 [15]. In addition, our data show that IL-1b
induced both CEBPb expression and phosphorylation at
threonine 235, an event required for CEBPb transcriptional activity (Fig. 4; [14, 25]). Importantly, shRNAmediated knockdown of CEBPb reduced IL-1b-induced
MMP-1, MMP-3, MMP-10, and MT1-MMP expression,
thereby identifying these MMPs as downstream targets of
CEBPb (Fig. 5).
In contrast to the secreted MMPs, IL-1b induction of
MT1-MMP was modest (Figs 2 and 3). This mild level
of induction is likely due to the constitutive expression of
MT1-MMP already present in these cells resulting from
the lack of VHL expression and activation of HIF-2a
[16]. In addition, MT1-MMP mRNA was not induced by
IL-1b until 24 h, whereas the mRNAs of the other MMPs
were induced as early as 2 h poststimulation (Fig. 3).
These results suggest that unlike MMP-1, MMP-3, MMP-10,
MT1-MMP may not be directly activated by CEBPb, but
activated in response to a downstream target of CEBPb.
One such candidate is IL-6, which is a well-described
transcriptional target of CEBPb [30]. In support of this
hypothesis, others have reported MT1-MMP as a downstream target of IL-6 signaling [31]. In addition, IL-6 was
potently
induced
by
IL-1b
in
a
CEBPbdependent manner by as early as 4 h posttreatment in
our experiments (data not shown).
Using RNA interference, we next demonstrated that
IL-1b-induced RCC tumor cell invasion required CEBPb
(Fig. 6). To our knowledge, this is the first report to
demonstrate a direct role for CEBPb in RCC tumor cell
invasion. These data identify CEBPb as an important
mediator of the response of tumor epithelial cells to an
inflammatory microenvironment. In agreement, others
have reported a direct correlation between increased
CEBPb activity in RCC patient tumors and the presence
of invasive disease [26]. Together, these findings provide
rationale for designing RCC therapies that target the
expression and/or activation of CEBPb.
The role for inflammation in the progression of
RCC is implicated by several clinical observations. For
example, high serum C-reactive protein (CRP), an acute
phase inflammatory protein, is a poor prognostic indicator for RCC [32–34]. High serum levels of the proinflammatory cytokines, IL-1b, IL-6, and TNFa, are also
associated with advanced disease [10]. In addition, the
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presence of TAMs in RCC tumors is considered a poor
prognostic indicator [8, 9], and inflammatory paraneoplastic syndromes are often associated with advanced
RCC [35]. The reported serum concentration of IL-1b
in metastatic RCC patients is approximately 500 ng/mL
[10]. In our assays, we measured a dramatic increase in
CEBPb and MMP expression in response to concentrations of IL-1b as low as 0.1 ng/mL. Although in vitro
and in vivo concentrations of IL-1b cannot be directly
compared, it is interesting to note the responsiveness of
the RCC cells to low IL-1b concentrations, which are
far below that which is detected in patients. We postulate that the proinflammatory milieu expressed by
TAMs in the tumor microenvironment has direct effects
on the gene expression profiles of RCC tumor cells,
thereby contributing to their progression to a metastatic
phenotype. In summary, our results implicate the IL1b/CEBPb/MMP signaling pathway as a major mediator
of RCC tumor cell invasion, and this pathway should
be considered in the design of preclinical models of
RCC to test its target-ability as an anti-metastatic
therapy.
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